Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126767402 | 12676740 | 2 | F | 20160725 | 20160817 | 20160823 | 20160831 | EXP | JP-009507513-1608JPN010873 | MERCK | 69.00 | YR | M | Y | 62.00000 | KG | 20160831 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126767402 | 12676740 | 1 | PS | REBETOL | RIBAVIRIN | 1 | Oral | 400 MG, BID | 14400 | MG | Y | 20903 | 400 | MG | CAPSULE | BID | |||
| 126767402 | 12676740 | 2 | SS | REBETOL | RIBAVIRIN | 1 | Oral | 400 MG, BID | 14400 | MG | Y | 20903 | 400 | MG | CAPSULE | BID | |||
| 126767402 | 12676740 | 3 | SS | SOVALDI | SOFOSBUVIR | 1 | Oral | 400 MG, QD | 7200 | MG | Y | 0 | 400 | MG | TABLET | QD | |||
| 126767402 | 12676740 | 4 | SS | SOVALDI | SOFOSBUVIR | 1 | Oral | 400 MG, QD | 7200 | MG | Y | 0 | 400 | MG | TABLET | QD | |||
| 126767402 | 12676740 | 5 | C | RABEPRAZOLE SODIUM. | RABEPRAZOLE SODIUM | 1 | Oral | 10 MG, PRN; DAILY DOSE UNKNOWN | 0 | 10 | MG | TABLET | |||||||
| 126767402 | 12676740 | 6 | C | DICLOFENAC SODIUM. | DICLOFENAC SODIUM | 1 | Oral | 37.5 MG, BID | 0 | 37.5 | MG | CAPSULE | BID | ||||||
| 126767402 | 12676740 | 7 | C | DICLOFENAC SODIUM. | DICLOFENAC SODIUM | 1 | Transdermal | DAILY DOSE UNKNOWN, AS REQUIRED, FORMULATION REPORTED AS CAPSULE | 0 | TRANSDERMAL PATCH | |||||||||
| 126767402 | 12676740 | 8 | C | OLMETEC | OLMESARTAN MEDOXOMIL | 1 | Oral | 10 MG, QD | 210 | MG | 0 | 10 | MG | TABLET | QD | ||||
| 126767402 | 12676740 | 9 | C | OLMETEC | OLMESARTAN MEDOXOMIL | 1 | Oral | 20 MG, QD | 210 | MG | 0 | 20 | MG | TABLET | QD | ||||
| 126767402 | 12676740 | 10 | C | REBAMIPIDE | REBAMIPIDE | 1 | Oral | 100 MG, BID | 0 | 100 | MG | TABLET | BID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126767402 | 12676740 | 1 | Chronic hepatitis C |
| 126767402 | 12676740 | 3 | Chronic hepatitis C |
| 126767402 | 12676740 | 5 | Gastrooesophageal reflux disease |
| 126767402 | 12676740 | 6 | Arthralgia |
| 126767402 | 12676740 | 7 | Arthralgia |
| 126767402 | 12676740 | 8 | Hypertension |
| 126767402 | 12676740 | 10 | Prophylaxis against gastrointestinal ulcer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126767402 | 12676740 | HO |
| 126767402 | 12676740 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126767402 | 12676740 | Pneumonia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126767402 | 12676740 | 1 | 20160708 | 20160802 | 0 | |
| 126767402 | 12676740 | 2 | 20160810 | 0 | ||
| 126767402 | 12676740 | 3 | 20160708 | 20160802 | 0 | |
| 126767402 | 12676740 | 4 | 20160810 | 0 | ||
| 126767402 | 12676740 | 5 | 20150723 | 0 | ||
| 126767402 | 12676740 | 6 | 20160705 | 0 | ||
| 126767402 | 12676740 | 8 | 20160709 | 20160721 | 0 | |
| 126767402 | 12676740 | 9 | 20160722 | 20160802 | 0 | |
| 126767402 | 12676740 | 10 | 20160705 | 0 |